Related Experiment Videos

Low mannose binding lectin predicts poor prognosis in patients with early rheumatoid arthritis. A prospective study

S Saevarsdottir1, T Vikingsdottir, A Vikingsson

  • 1Department of Immunology, Landspitalinn University Hospital, Reykjavik, Iceland.

Abstract

Insights

Low mannose binding lectin (MBL) levels predict a poorer prognosis in rheumatoid arthritis (RA) patients, indicating worse disease progression and joint damage. MBL deficiency was not more frequent in RA patients than controls.

Area of Science:

  • Immunology
  • Rheumatology

Background:

  • Mannose binding lectin (MBL) plays a role in innate immunity.
  • MBL deficiency may influence autoimmune disease development and progression.

Purpose of the Study:

  • To investigate the association between low MBL levels and prognosis in rheumatoid arthritis (RA).
  • To determine if RA patients exhibit a higher frequency of MBL deficiency.

Main Methods:

  • Early arthritis patients (<1 year symptom duration) were assessed for MBL concentration, rheumatoid factor (RF) isotypes, and C-reactive protein (CRP).
  • Disease activity and progression (joint scores, grip strength, radiological erosions) were evaluated after 6 months.
  • Advanced RA patients were also analyzed for MBL association with radiological damage.

Main Results:

  • Low MBL levels correlated with elevated RF, particularly IgA RF, and combined IgM/IgA RF.
  • Patients with low MBL showed less improvement in joint scores and grip strength over 6 months.
  • Low MBL was significantly associated with radiological joint erosions at baseline and follow-up in early RA, and with radiological damage in advanced RA.
  • No increased frequency of MBL deficiency was observed in RA patients compared to healthy controls.

Conclusions:

  • Low MBL concentration is a predictor of poor prognosis in early rheumatoid arthritis.
  • Low MBL is linked to increased disease activity, poorer treatment response, and greater radiological damage in RA.

Related Concept Videos